These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3901047)

  • 1. Pharmacobiochemistry of arylalkyltriazenes and their application in cancer chemotherapy.
    Spassova MK; Golovinsky EV
    Pharmacol Ther; 1985; 27(3):333-52. PubMed ID: 3901047
    [No Abstract]   [Full Text] [Related]  

  • 2. Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study.
    Venger BH; Hansch C; Hatheway GJ; Amrein YU
    J Med Chem; 1979 May; 22(5):473-6. PubMed ID: 379331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [DTIC and its derivatives: cytotoxic or antimetastatic drugs?].
    Giraldi T; Sava G; Perissin L; Zorzet S; Tamaro M; Dolzani L
    G Ital Chemioter; 1985; 32(1):43-7. PubMed ID: 3830793
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic activation of triazene cytostatics.
    Kolar GF; Wildschütte M
    Adv Exp Med Biol; 1981; 136 Pt B():1285-96. PubMed ID: 7344512
    [No Abstract]   [Full Text] [Related]  

  • 5. Carcinogenicity of cytostatic triazenes.
    Kolar GF
    IARC Sci Publ; 1986; (78):111-26. PubMed ID: 3583385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.
    Cameron LM; LaFrance RJ; Hemens CM; Vaughan K; Rajaraman R; Chubb DC; Goddard PM
    Anticancer Drug Des; 1985 Oct; 1(1):27-36. PubMed ID: 3870878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of selected fetal organs to antineoplastic agents.
    Chaube S; Swinyard CA
    Life Sci; 1976 Jul; 19(1):77-83. PubMed ID: 940436
    [No Abstract]   [Full Text] [Related]  

  • 8. Diazoaminobenzene.
    Rep Carcinog; 2004; 11():III80-1. PubMed ID: 21089848
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis of triazenoazaindoles: a new class of triazenes with antitumor activity.
    Diana P; Stagno A; Barraja P; Carbone A; Parrino B; Dall'Acqua F; Vedaldi D; Salvador A; Brun P; Castagliuolo I; Issinger OG; Cirrincione G
    ChemMedChem; 2011 Jul; 6(7):1291-9. PubMed ID: 21523910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
    Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
    Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutagenicity of dimethyl heteroaromatic triazenes in the Ames test: the role of hydrophobicity and electronic effects.
    Shusterman AJ; Debnath AK; Hansch C; Horn GW; Fronczek FR; Greene AC; Watkins SF
    Mol Pharmacol; 1989 Dec; 36(6):939-44. PubMed ID: 2601689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Triazenes: from Bioprecursors to Hybrid Molecules.
    Francisco AP; Mendes E; Santos AR; Perry MJ
    Curr Pharm Des; 2019; 25(14):1623-1642. PubMed ID: 31244412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR in cancer chemotherapy.
    Hansch C
    Farmaco Sci; 1979 Jan; 34(1):89-104. PubMed ID: 399923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
    Nicolin A; Fagnani R; Nicolotti G; Goldin A
    Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cluster analysis in the development of structure-activity relations for antitumor triazenes.
    Dunn WJ; Greenberg MJ; Callejas SS
    J Med Chem; 1976 Nov; 19(11):1299-301. PubMed ID: 1003406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrugs in cancer chemotherapy.
    Wilman DE
    Biochem Soc Trans; 1986 Apr; 14(2):375-82. PubMed ID: 3086154
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
    Wilman DE; Goddard PM
    J Med Chem; 1980 Sep; 23(9):1052-4. PubMed ID: 7411549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
    Foster BJ; Newell DR; Carmichael J; Harris AL; Gumbrell LA; Jones M; Goodard PM; Calvert AH
    Br J Cancer; 1993 Feb; 67(2):362-8. PubMed ID: 8431367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-triazenoindoles: synthesis and biological activity.
    Barraja P; Diana P; Lauria A; Montalbano A; Almerico AM; Dattolo G; Cirrincione G
    Anticancer Res; 2002; 22(2A):837-40. PubMed ID: 12014660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice.
    Giraldi T; Houghton PJ; Taylor DM; Nisi C
    Cancer Treat Rep; 1978 May; 62(5):721-5. PubMed ID: 657157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.